BCR and acute lymphoblastic leukemia: In particular, BCR-ABL fusion gene-positive ALL (BCR-ABL+ ALL) accounts for 20–30% of ALL in adults and approximately 3–5% of ALL in children, with the poor effect of conventional chemotherapy, highly susceptible to relapse, and extremely poor prognosis [139].